Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod. For the quarter, Fischer reported sales of
Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod.
For the quarter, Fischer reported sales of $21.9 million, upsharply from the $18.1 million posted in the second quarter of1995. Net income stood at $946,000, compared with $397,000 inthe same period the year before.
Fischer chairman and CEO Morgan Nields reported that Fischer'sSenoScan full-field digital mammography program is moving forward:Fischer is planning to ship its second clinical trial unit inthe next several weeks, with clinical trials to follow. Fischerplans to submit a regulatory application for the system in thesecond half of this year, with clearance expected in 1997.
Fischer earlier this month completed a secondary stock offeringthat raised $13.5 million. The company is now virtually debt-freeand has cash on hand to fund growth opportunities, according toCFO Jim Newcomb.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.